课题基金 / 基金详情

VACCINE USING HIV/SIV ENV, GAG, NEF & TAT ADENOVIRUS WITH PROTEIN BOOSTING

VACCINE USING HIV/SIV ENV, GAG, NEF & TAT ADENOVIRUS WITH PROTEIN BOOSTING
使用 HIV/SIV ENV、GAG、NEF 进行疫苗
批准号:
7349364
负责人:
Marjorie Robert-Guroff
金额:
$22.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2007-04-30
关键词:

项目摘要

项目成果

Marjorie Robert-Guroff的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。我们评估了具有复制能力的Ad5宿主范围突变重组体(Ad5hr)的免疫原性。观察静脉注射SHIV89.6P攻击的疗效。用Ad5hr编码HIVtat(第1组)、HIVtat + HIV89.6Penv(第2组)或HIVtat + HIV89.6Penv + SIV239gag + SIV239nef(第3组)对恒河猴(每组8只)进行鼻内(第0周)和气管内(第12周)启动。蛋白亚单位增强(第24周和第36周),根据Ad引物给予,包括HIV Tat(明矾,SC), HIV89.6pgp140和SIV239 Nef,均在MPL-SE, IM中给予。对照动物仅注射Ad5hr- E3和佐剂。用30 MID50 SHIV89.6P刺激猕猴(第50周)。ELISPOT检测到的特异性IFN-分泌细胞在免疫过程中呈低水平和零星分布。应答者的数量在3个接种组中相似(I-III组分别为7/8、6/8和6/8只猕猴)。特异性的增殖反应也是零星的,频率较低,各组间的有效率相似(I-III组分别为3/8、4/8和4/8)。II组(that / Env)和III组(that / Env /gag/nef)对Env肽产生了有效的细胞免疫反应。III组ELISPOT对Gag的反应一般,对Nef的反应可以忽略不计。II组和III组对灭活SHIV89.6P均有增殖反应,III组对p27和Nef分别有4/8和7/8反应。所有猕猴都产生了针对各自蛋白质增强剂的结合抗体。3组抗tat滴度相似,II组和III组抗env滴度相似。III组的所有猕猴都对Nef产生了强烈的抗体反应
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We evaluated the immunogenicity of replication-competent Ad5 host range mutant recombinants (Ad5hr). Efficacy against intravenous SHIV89.6P challenge was tested. Rhesus macaques (8 per group) were primed intranasally (wk 0) and intratracheally (wk 12) with Ad5hr encoding HIVtat (group I), HIVtat + HIV89.6Penv (group II), or HIVtat + HIV89.6Penv + SIV239gag + SIV239nef (group III). Protein subunit boosts (wks 24 and 36), given according to the Ad prime, consisted of HIV Tat (in alum, SC), and HIV89.6pgp140 and SIV239 Nef , both given in MPL-SE, IM. Control animals received Ad5hr-'E3 and adjuvant only. Macaques were challenged (wk 50) with 30 MID50 SHIV89.6P. Tat-specific IFN- ' -secreting cells measured by ELISPOT were low and sporadic over the course of immunization. The number of responders was similar in the 3 vaccination groups (7/8, 6/8, and 6/8 macaques in groups I-III, respectively). Tat-specific proliferative responses were also sporadic and less frequent, with a similar response rate among groups (3/8, 4/8, and 4/8 responders in groups I-III, respectively). Potent cellular immune responses to Env peptides were seen in group II (tat/env) and III (tat/env/gag/nef). In Group III ELISPOT responses were modest to Gag and negligible to Nef. All macaques in groups II and III exhibited proliferative responses to inactivated SHIV89.6P, and in group III, 4/8 and 7/8 responded to p27 and Nef, respectively. All macaques developed binding antibodies to their respective protein boosters. Anti-Tat titers were similar in the 3 groups, and comparable anti-Env titers were exhibited in groups II and III. All macaques in group III mounted a strong antibody response to Nef
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VACCINE USING HIV/SIV ENV, GAG, NEF & TAT ADENOVIRUS WITH PROTEIN BOOSTING
  • 批准号:
    7958842
  • 项目类别:
  • 资助金额:
    $49.71万
  • 财政年份:
    2009
  • 负责人:
    Marjorie Robert-Guroff
  • 依托单位:
VACCINE USING HIV/SIV ENV, GAG, NEF & TAT ADENOVIRUS WITH PROTEIN BOOSTING
  • 批准号:
    7716363
  • 项目类别:
  • 资助金额:
    $37.15万
  • 财政年份:
    2008
  • 负责人:
    Marjorie Robert-Guroff
  • 依托单位:
VACCINE USING HIV/SIV ENV, GAG, , NEF AND TAT ADENOVIRUS RECOMBINANTS
  • 批准号:
    7165825
  • 项目类别:
  • 资助金额:
    $17.73万
  • 财政年份:
    2005
  • 负责人:
    Marjorie Robert-Guroff
  • 依托单位:
Development of a Vaccine for HIVAIDS: Cellular Immunity
  • 批准号:
    8349307
  • 项目类别:
  • 资助金额:
    $169.69万
  • 财政年份:
    --
  • 负责人:
    Marjorie Robert-Guroff
  • 依托单位:
国内基金
海外基金
Capture and Release of Droplets Using Advanced Materials for High Technology Applications
  • 批准号:
    52073127
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    Alidad Amirfazli
  • 依托单位:
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data